MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Cytek Biosciences Inc

Fermé

SecteurSoins de santé

5.39 -3.92

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.38

Max

5.48

Chiffres clés

By Trading Economics

Revenu

105K

-5.5M

Ventes

6.7M

52M

BPA

-0

Marge bénéficiaire

-10.476

Employés

692

EBITDA

6.4M

-4.2M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+10.97% upside

Dividendes

By Dow Jones

Prochains Résultats

26 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

240M

742M

Ouverture précédente

9.31

Clôture précédente

5.39

Sentiment de l'Actualité

By Acuity

17%

83%

18 / 361 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Cytek Biosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 janv. 2026, 23:29 UTC

Actions en Tendance

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 janv. 2026, 22:48 UTC

Acquisitions, Fusions, Rachats

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 janv. 2026, 22:43 UTC

Acquisitions, Fusions, Rachats

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 janv. 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

16 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Auto & Transport Roundup: Market Talk

16 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 janv. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 janv. 2026, 21:48 UTC

Market Talk
Acquisitions, Fusions, Rachats

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 janv. 2026, 21:41 UTC

Market Talk
Acquisitions, Fusions, Rachats

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 janv. 2026, 21:38 UTC

Acquisitions, Fusions, Rachats

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 janv. 2026, 20:44 UTC

Résultats

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 janv. 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 janv. 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 janv. 2026, 19:12 UTC

Market Talk
Acquisitions, Fusions, Rachats

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 janv. 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 janv. 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 janv. 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 janv. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16 janv. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 janv. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16 janv. 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16 janv. 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 janv. 2026, 16:32 UTC

Market Talk
Acquisitions, Fusions, Rachats

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 janv. 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparaison

Variation de prix

Cytek Biosciences Inc prévision

Objectif de Prix

By TipRanks

10.97% hausse

Prévisions sur 12 Mois

Moyen 6.17 USD  10.97%

Haut 7.5 USD

Bas 5 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

3.7 / 3.8Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

18 / 361Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat